Iloprost for idiopathic pulmonary arterial hypertension

References

• D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115, 343–349 (1991).
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43, S5–S12 (2004).
   PubMed Web of Science ®Google Scholar
• Rubin LJ. Primary pulmonary hypertension. N. Engl. J. Med. 336, 111–117 (1997).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rose F, Grunig E et al. Cellular pathophysiology and therapy of pulmonary hypertension. J. Lab. Clin. Med. 138, 367–377 (2001).
   PubMed Web of Science ®Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327, 76–81 (1992).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jagot JL et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension. Eur. Respir. J. 12, 265–270 (1998).
   PubMed Web of Science ®Google Scholar
• Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70, 580–587 (1984).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334, 296–302 (1996).
   PubMed Web of Science ®Google Scholar
• Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am. J. Respir. Crit. Care Med. 167, 580–586 (2003).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132, 425–434 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99, 1858–1865 (1999).
   PubMed Web of Science ®Google Scholar
• Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63, 604–106 (1997).
   PubMed Web of Science ®Google Scholar
• Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med. 162, 1846–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rose F, Schermuly R et al. Prostacyclin and its analogs in the treatment of pulmonary hypertension. Pharmacol. Ther. 102, 139–153 (2004).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121, 409–415 (1994).
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery J et al. Effects of beraprost sodium, an oral prostacyclin analog, in patients with pulmonary artery hypertension: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 39, 1496–1502 (2002).
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165, 800–804 (2002).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322–329 (2002).
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 358, 1119–1123 (2001).
   PubMed Web of Science ®Google Scholar
• Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 43, 1149–1153 (2004).
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351, 1425–1436 (2004).
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41, 2119–2125 (2003).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896–903 (2002).
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Sitbon O, Rubin LJ. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 167 (2003) (Abstract).
   PubMedGoogle Scholar
• Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169, 441–447 (2004).
   PubMed Web of Science ®Google Scholar
• Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 126, 1377–1381 (2004).
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide and iloprost in primary pulmonary hypertension. Chest 125, 580–586 (2004).
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Tymchak W, Noga M et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108, 2066–2069 (2003).
   PubMed Web of Science ®Google Scholar
• Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104, 1218–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136, 515–522 (2002).
   PubMed Web of Science ®Google Scholar
• Pomeranz HD, Smith KH, Hart J, Egan RA. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 109, 584–587 (2002).
   PubMed Web of Science ®Google Scholar
• Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic amp generation in human pulmonary artery. Am. J. Respir. Cell. Mol. Biol. 26, 194–201 (2002).
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol. Rev. 79, 1193–1226 (1999).
   PubMed Web of Science ®Google Scholar
• Turcato S, Clapp LH. Effects of the adenyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta. Br. J. Pharmacol. 126, 845–847 (1999).
   PubMed Web of Science ®Google Scholar
• Clapp LH, Turcato S, Hall S, Baloch M. Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost. Eur. J. Pharmacol. 356, 215–224 (1998).
   PubMed Web of Science ®Google Scholar
• Rose F, Hattar K, Gakisch S et al. Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost. Thromb. Haemostas. 90, 1141–1149 (2003).
   PubMed Web of Science ®Google Scholar
• Beghetti M, Reber G, de Moerloose P et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur. Respir. J. 19, 518–524 (2002).
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Kreisselmeier KP, Ghofrani HA et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. 94, 1101–1108 (2004).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur. Respir. J. 20, 339–343 (2002).
   PubMed Web of Science ®Google Scholar
• Ewert R, Opitz C, Wensel R et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol. 89, 987–999 (2000).
   PubMedGoogle Scholar
• Olschewski H, Ghofrani HA, Walmrath D et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 160, 600–607 (1999).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Friese G, Discher T et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur. Respir. J. 23, 321–326 (2004).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med. 124, 820–824 (1996).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med. 24, 631–634 (1998).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med. 132, 435–443 (2000).
   PubMed Web of Science ®Google Scholar
• Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analog iloprost in man. Eur. J. Clin. Pharmacol. 30, 61–68 (1986).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol. 35, 176–182 (2000).
   PubMed Web of Science ®Google Scholar
• Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolized prostacyclin in adult respiratory distress syndrome. Lancet 342, 961–962 (1993).
   PubMed Web of Science ®Google Scholar
• Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur. Respir. J. 10, 1084–1092 (1997).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 124, 1294–1304 (2003).
   PubMed Web of Science ®Google Scholar
• Gessler T, Schmehl T, Hoeper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J. 17, 14–19 (2001).
   PubMed Web of Science ®Google Scholar
• Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am. J. Respir. Crit. Care Med. 151, 724–730 (1995).
   PubMed Web of Science ®Google Scholar
• Zwissler B, Kemming G, Habler O et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 154, 1671–1677 (1996).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analog. N. Engl. J. Med. 342, 1866–1870 (2000).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Nikkho S, Behr J et al. Long-term survival in patients with pulmonary hypertension inhaling iloprost. European Society of Cardiology Congress. Vienna, Austria, 30 August–3 September 2000 (Abstract 2567).
   Google Scholar
• Sitbon O, Humbert M, Ioos V et al. Who benefits from long-term calcium channel-blocker therapy in primary pulmonary hypertension? Am. J. Respir. Crit. Care Med. (2003) (Abstract A440).
   PubMedGoogle Scholar
• Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from iv. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 121, 1561–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42, 158–164 (2003).
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 24, 353–359 (2004).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 24, 1007–1010 (2004).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102, 865–870 (2000).
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Holzapfel M, Baumgartner RA et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Am. Coll. Cardiol. 43, 764–770 (2004).
   PubMed Web of Science ®Google Scholar
• Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, S81–S88 (2004).
   PubMed Web of Science ®Google Scholar